Prof. Hui Zhou 周辉
Chief Physician, Professor
Department of Medical Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Lymphoma, multiple myeloma, and head and neck tumors. Treatments include chemotherapy, targeted therapy, immunotherapy, and hematopoietic stem cell transplantation.
Dr. Zhou holds a PhD and serves as Professor and Chief Physician. As Director of the Lymphoma and Hematology Department and the Hunan Provincial Lymphoma Diagnosis and Treatment Center, Dr. Zhou supervises master's students. Research includes over 10 provincial-level projects and more than 50 publications. Recipient of the Third Prize of the Hunan Medical Science and Technology Award. Outpatient clinic: Monday mornings.
Professional roles
- Chair, Lymphoma Professional Committee, Hunan Anti-Cancer Association
- Standing Committee Member, Lymphoma Professional Committee, China Anti-Cancer Association
- Member, Lymphoma Group, Oncology Branch, Chinese Medical Association
- Member, Anti-Lymphoma Alliance and Anti-Leukemia Alliance, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Zhou Hui). Papers usually list the name as Hui Zhou or Zhou H.
Selected publications
105 papers on PubMed matched by name and affiliation; 17 as first or senior author since 2016. Most recent first- or senior-author papers:
- Crit Rev Oncol Hematol, 2026 (senior author): Targeting metabolic reprogramming in multiple myeloma: Molecular mechanisms and potential therapeutic targets. PubMed 41806908
- MedComm (2020), 2026 (senior author): Protein Lactylation in Cancer: Mechanisms and Therapeutic Targets. PubMed 41822903
- Cancer Cell Int, 2025 (senior author): Genomic signatures in plasma circulating tumor DNA reveal treatment response and prognostic insights in mantel cell lymphoma. PubMed 40319323
- Hum Vaccin Immunother, 2024 (senior author): A novel anti-CD47 antibody with therapeutic potential for NK/T-cell lymphoma. PubMed 39348228
- Leukemia, 2024 (senior author): Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK/T-cell lymphoma. PubMed 38783159
- Funct Integr Genomics, 2024 (senior author): Retraction Note: Identification of biomarkers of hepatocellular carcinoma gene prognosis based on the immune-related lncRNA signature of transcriptome data. PubMed 38730114
- Drug Des Devel Ther, 2023 (first author): Informatics on Drug Repurposing for Breast Cancer. PubMed 37405253
- Funct Integr Genomics, 2023 (senior author): Correction to: Identification of biomarkers of hepatocellular carcinoma gene prognosis based on the immune‑related lncRNA signature of transcriptome data. PubMed 37160489
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers; we checked the papers' affiliations and topics against this doctor's department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion